Thyroid cancer

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
6 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
V Various (ATC V) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Kinase inhibitor 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 3 Phase II: 1 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

3 trials
  • Exelixis Inc. Commercial
    CABOZANTINIB
    2024-516478-31-00 3 countries 2019 n=6
    Ended
  • Centre Francois Baclesse Academic
    SODIUM IODIDE (131I)
    2024-514603-34-00 1 country 2020 n=476
    Recruiting
  • Medical University Of Bialystok Academic
    METFORMIN HYDROCHLORIDE
    2024-518352-23-00 1 country 2022 n=160
    Recruiting

Phase II

1 trial
  • Grupo Espanol De Tumores Neuroendocrinos Academic
    CABOZANTINIB
    2024-511292-15-00 1 country 2023 n=41
    Ended

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Exelixis Inc. Commercial 1 Phase III 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 0
Grupo Espanol De Tumores Neuroendocrinos Academic 1 Phase II 0
Centre Francois Baclesse Academic 1 Phase III 1
Medical University Of Bialystok Academic 1 Phase III 1
New trials by year
2019
1
2020
1
2022
2
2023
1
← All indication landscapes